2m 2m 2m 2m 2m 2m 2m
UNICYCIVE THERAP (UNCY)
NASDAQ
$7.16-$0.04 (-0.57%)
Price as of Jun 03, 2026 7:55 PM EDT- $197.0MMarket Cap
- -7.10%1-Year Change
- BiotechnologyIndustry
UNICYCIVE THERAP (UNCY)
$7.16-$0.04 (-0.57%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 675,000 -29.02% | 951,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | 10.0M N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 +100.00% | -9.3M -1,080.55% | 951,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | 383,000 +56.33% | |
Research and Development Expense | -9.1M -54.43% | -20.0M +55.12% | -12.9M +3.75% | -12.4M +104.54% | |
Depreciation and Amortization Expense | 34,000 +54.55% | 22,000 +144.44% | 9,000 +28.57% | 7,000 -98.50% | |
Total Operating Expenses | 29.5M -8.10% | 32.1M +49.74% | 21.4M +12.87% | 19.0M +111.69% | |
Operating Profit | -29.5M -8.10% | -32.1M +54.60% | -20.8M +15.08% | -18.1M +101.09% | |
Interest Income | 1.0M -19.75% | 1.3M +105.04% | 615,000 N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -82,000 +1,266.67% | -6,000 -99.04% | |
Interest Income and Expense and Net | 1.0M -19.75% | 1.3M +136.59% | 533,000 +8,983.33% | -6,000 -99.04% | |
Total Nonoperating Income and Expense | 3.0M +164.22% | -4.6M -52.79% | -9.8M +162,733.33% | -6,000 -99.42% | |
Income before Taxes | -26.6M -29.79% | -37.8M +20.42% | -31.4M +74.00% | -18.1M +101.09% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -26.6M -27.70% | -36.7M +20.25% | -30.5M +69.14% | -18.1M +80.27% | |
Net Income from Continuing Operations Applicable to Common | -26.6M -29.79% | -37.8M +20.42% | -31.4M +73.95% | -18.1M +80.27% | |
Basic EPS and Net Income | -1.67 +198.21% | -0.56 -56.25% | -1.28 +6.67% | -1.20 +39.53% | |
Diluted EPS and Net Income | -1.67 +198.21% | -0.56 -56.25% | -1.28 +6.67% | -1.20 +39.53% | |
Basic Weighted Average Shares | 15.9M -76.28% | 67.0M +172.97% | 24.5M +62.98% | 15.1M +28.96% | |
Diluted Weighted Average Shares | 15.9M -76.28% | 67.0M +172.97% | 24.5M +62.98% | 15.1M +28.96% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 29.2M +11.69% | 26.1M +169.48% | 9.7M +2,032.09% | 455,000 -97.26% | |
Short-Term Investments | 12.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 41.3M +57.86% | 26.1M +169.48% | 9.7M +2,032.09% | 455,000 -97.26% | |
Total Current Assets | 49.0M +58.20% | 30.9M +130.97% | 13.4M +406.77% | 2.6M -85.64% | |
Accumulated Depreciation | 72,000 +84.62% | 39,000 +143.75% | 16,000 +128.57% | 7,000 +600.00% | |
Property and Plant and Equipment and Net | 66,000 -12.00% | 75,000 +188.46% | 26,000 +18.18% | 22,000 -21.43% | |
Total Long-Term Assets | 66,000 -12.00% | 75,000 +188.46% | 26,000 +18.18% | 22,000 -21.43% | |
Total Assets | 49.1M +55.16% | 31.7M +123.16% | 14.2M +403.58% | 2.8M -84.97% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 18.9M -21.48% | 24.1M +37.56% | 17.5M +433.92% | 3.3M +56.01% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | 18,000 N/A | |
Total Long-Term Liabilities | 16.9M -11.22% | 19.1M +40.10% | 13.6M +8,674.19% | 155,000 0.00% | |
Total Liabilities | 18.9M -21.86% | 24.2M +34.65% | 18.0M +448.11% | 3.3M +45.31% | |
Retained Earnings | -127.8M +26.22% | -101.3M +56.91% | -64.5M +89.84% | -34.0M +113.29% | |
Total Stockholders Equity | 30.2M +306.37% | 7.4M +295.09% | -3.8M +717.38% | -466,000 -102.83% | |
Total Shares Outstanding | 22.1M -80.57% | 113.8M +227.55% | 34.8M +128.18% | 15.2M +1.57% | |
Cash Flow | |||||
Cash from Operating Activities | -31.3M +9.60% | -28.6M +56.29% | -18.3M +16.82% | -15.7M +171.39% | |
Capital Expenditures | 24,000 -66.67% | 72,000 +500.00% | 12,000 +500.00% | 2,000 N/A | |
Cash from Investing Activities | -12.1M +16,698.61% | -72,000 +500.00% | -12,000 +500.00% | -2,000 -93.10% | |
Dividends Paid | N/A N/A | 1.1M +21.67% | 900,000 N/A | N/A N/A | |
Cash from Financing Activities | 46.5M +3.06% | 45.1M +63.71% | 27.5M +5,947.35% | -471,000 -102.11% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | -1,381.48% N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -3,077.63% +62.13% | -1,898.21% N/A | |
Return on Assets | -65.73% -58.97% | -160.18% -55.40% | -359.15% +114.42% | -167.50% N/A | |
Return on Equity | -141.14% -93.04% | -2,028.11% -241.93% | 1,428.96% +733.77% | -225.47% N/A | |
Revenue Growth | N/A N/A | N/A N/A | -29.02% N/A | N/A N/A | |
Current Ratio | 2.59 +101.49% | 1.28 +67.90% | 0.76 -5.08% | 0.81 N/A | |
Cash Ratio | 1.54 +42.26% | 1.08 +95.88% | 0.55 +299.21% | 0.14 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow